Genome Life Sciences

genomels.com

Genome Life Sciences (GLS) is a DSIR-recognized Genomics & Biomarker discovery company and a prominent provider of start-to-finish Next-Generation Sequencing and data analysis services, custom database development, contract research and bioinformatics consulting. The company provides life science databases of unique content developed with data mining algorithms along with their interactive and dynamic user interfaces. GLS helps customers worldwide meet the bioinformatics challenges with its powerful tools and technologies. Our clients include academia, federal and private industries from USA and Europe.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

HEALTHMYNE'S RADIOMIC TECHNOLOGY LEVERAGED TO IDENTIFY BIOMARKERS THAT PREDICT IMMUNOTHERAPY TREATMENT RESPONSES

HealthMyne | September 22, 2021

news image

HealthMyne, a pioneer in applied radiomics, announced that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy. In the Cancers article, researchers led by Vincenza Granata evaluated HealthMyne's technology as a quantitative imaging decision support tool for radiomic analysis of lung adenocarcinoma i...

Read More

WITH AN EYE ON THE CLINIC, ATLAS-BACKED KYMERA SECURES $102 MILLION

BioSpace | March 12, 2020

news image

Cambridge, Mass.-based Kymera Therapeutics closed a $102 million Series C funding round to continue advancing the company’s lead targeted protein degradation asset for oncology and immunology. Kymera's lead program targets IRAK4, a protein that is known to play a significant role in inflammation that is mediated by toll-like and IL-1 receptors. Kymera aims to advance its IRAK4 degrader program in a variety of autoinflammatory and autoimmune diseases, as well as in precision-medicine ta...

Read More

Cell and Gene Therapy

CELLISTIC AND CELYAD ONCOLOGY ANNOUNCE GMP CELL THERAPY MANUFACTURING OPERATIONS TRANSACTION

Cellistic and Ncardia | September 20, 2022

news image

Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice grade cell therapy manufacturing capability, including the existing facility and all related personnel. Under the terms of an asset ...

Read More

PHARMAMAR/JAZZ PHARMACEUTICALS GET NDA PRIORITY FOR LUNG CANCER DRUG

European Biotechnology | February 17, 2020

news image

PharmaMar and Jazz Pharmaceuticals have received FDA Priority Review of a NDA for lurbinectedin in relapsed SCLC (Small Cell Lung Cancer). The PDUFA date was set for August 16, 2020 by the US Food and Drug Administration (FDA) for lurbinectedin as second-line treatment for patients with SCLC who relapsed following platium-based chemotherapy. The synthetic drug developed by PharmaMar SA (Madrid, Spain) and exclusively licenced by Jazz Pharmaceuticals plc (Dublin, Ireland) in December 2019 works b...

Read More
news image

Medical

HEALTHMYNE'S RADIOMIC TECHNOLOGY LEVERAGED TO IDENTIFY BIOMARKERS THAT PREDICT IMMUNOTHERAPY TREATMENT RESPONSES

HealthMyne | September 22, 2021

HealthMyne, a pioneer in applied radiomics, announced that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy. In the Cancers article, researchers led by Vincenza Granata evaluated HealthMyne's technology as a quantitative imaging decision support tool for radiomic analysis of lung adenocarcinoma i...

Read More
news image

WITH AN EYE ON THE CLINIC, ATLAS-BACKED KYMERA SECURES $102 MILLION

BioSpace | March 12, 2020

Cambridge, Mass.-based Kymera Therapeutics closed a $102 million Series C funding round to continue advancing the company’s lead targeted protein degradation asset for oncology and immunology. Kymera's lead program targets IRAK4, a protein that is known to play a significant role in inflammation that is mediated by toll-like and IL-1 receptors. Kymera aims to advance its IRAK4 degrader program in a variety of autoinflammatory and autoimmune diseases, as well as in precision-medicine ta...

Read More
news image

Cell and Gene Therapy

CELLISTIC AND CELYAD ONCOLOGY ANNOUNCE GMP CELL THERAPY MANUFACTURING OPERATIONS TRANSACTION

Cellistic and Ncardia | September 20, 2022

Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice grade cell therapy manufacturing capability, including the existing facility and all related personnel. Under the terms of an asset ...

Read More
news image

PHARMAMAR/JAZZ PHARMACEUTICALS GET NDA PRIORITY FOR LUNG CANCER DRUG

European Biotechnology | February 17, 2020

PharmaMar and Jazz Pharmaceuticals have received FDA Priority Review of a NDA for lurbinectedin in relapsed SCLC (Small Cell Lung Cancer). The PDUFA date was set for August 16, 2020 by the US Food and Drug Administration (FDA) for lurbinectedin as second-line treatment for patients with SCLC who relapsed following platium-based chemotherapy. The synthetic drug developed by PharmaMar SA (Madrid, Spain) and exclusively licenced by Jazz Pharmaceuticals plc (Dublin, Ireland) in December 2019 works b...

Read More